Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Clinical Pharmacology & Therapeutics2015Vol. 98(2), pp. 127–134
Citations Over TimeTop 1% of 2015 papers
J K Hicks, JR Bishop, Katrin Sangkuhl, Müller Dj, Yuan Ji, SG Leckband, JS Leeder, RL Graham, DL Chiulli, Adrián LLerena, TC Skaar, Stuart A. Scott, Julia Stingl, Teri E. Klein, KE Caudle, Andrea Gaedigk
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).
Related Papers
- → The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats(2003)166 cited
- → R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram(2004)54 cited
- → R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model(2003)51 cited
- → The Discovery of Citalopram and Its Refinement to Escitalopram(2012)7 cited
- A control study of escitalopram versus citalopram in treatment of generalized anxiety disorder(2009)